BRACKNELL, UNITED KINGDOM – July 7, 2011 – Quintiles today reached a significant milestone in its prime site program with the official opening of a clinical research facility within Queen Mary, University of London.
Queen Mary was Quintiles’ first prime site, with the collaboration dating back to 2007. Prime Sites are large clinical institutions that collaborate with Quintiles to drive productivity and excellence in clinical research. Quintiles provides dedicated resources to the clinical research facility to maximize patient recruitment and accelerate outcomes.
“In the New Health, there is significant pressure to speed the drug development process in order to develop treatments that enable people to live healthier lives,” said Lindy Jones, Global Head of Integrated Site Services. “We are proud to be working with the team at Queen Mary to further enhance our ability to recruit patients and investigators who are critical to an efficient and effective drug development process.”
Since 2008 the site has consistently delivered a significant proportion of the patients enrolled in the UK and enrollment numbers are ahead of other sites around the globe. In 2011 to date the site has recruited more than 10 percent of UK patients enrolled in Quintiles studies. Investigators at Queen Mary work on at least 20 studies at any one time, across multiple therapeutic areas, with best in class start-up timelines.
Mark Caulfield, Director of William Harvey Research Institute and The NIHR Cardiovascular Biomedical Research Unit at Queen Mary, said: “We are delighted to be working with Quintiles who, like ourselves have the patient at the heart of everything they do. This center will enhance collaboration between medical and clinical research professionals and academics across a range of protocols and therapeutic areas.
“Quintiles was one of six donors to the center, which aims to provide a research pipeline whereby the innovation of new therapeutics can be converted from laboratory to patient in one unique environment.”
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.